Loading...
ACOR.Q logo

Acorda Therapeutics, Inc.OTCPK:ACOR.Q Stock Report

Market Cap US$37.4k
Share Price
n/a
My Fair Value
n/a
1Y-99.9%
7D-28.5%
1D
Portfolio Value
​
View

Acorda Therapeutics, Inc.

OTCPK:ACOR.Q Stock Report

Market Cap: US$37.4k

Acorda Therapeutics (ACOR.Q) Stock Overview

A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. More details

ACOR.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Negative shareholders equity

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months

Does not have a meaningful market cap ($37K)


ACOR.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Acorda Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Acorda Therapeutics
Historical stock prices
Current Share PriceUS$0.02
52 Week HighUS$18.00
52 Week LowUS$0.013
Beta1.69
1 Month Change-84.62%
3 Month Change-96.88%
1 Year Change-99.88%
3 Year Change-99.97%
5 Year Change-99.99%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Analysis Article • Feb 21

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Dec 18

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Acorda Therapeutics, Inc. ( NASDAQ:ACOR ) shareholders are no doubt pleased to see that the share price has bounced 53...
Analysis Article • Jun 05

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Oct 17

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Acorda Therapeutics (NASDAQ:ACOR), a biotech focused on neurological disorders, announced Sunday that a panel of arbitrators awarded it $16.5M from Alkermes (ALKS) in connection with a licensing dispute between the two over multiple sclerosis therapy Ampyra. ACOR shares added ~46% pre-market on Monday in reaction to the news. The decision comes after ACOR sought the intervention of the American Arbitration Association in July 2020 following a dispute with ALKS with the expiration of an Ampyra patent in 2018. The ruling requires ALKS to pay $15M to cover past royalties and $1.5M as prejudgment interest to ACOR. In addition, ACOR will be free to use alternative supplies of Ampyra and will not have to pay ALKS any royalties on net sales for licensing and supplies. Also known as dalfampridine, Ampyra is marketed as Fampyra outside the U.S. by Biogen (BIIB). The extended-release tablet formulation is indicated in the U.S. to improve walking in adults with multiple sclerosis. In 2021, ACOR generated $84.6M of net revenue from Ampyra in the U.S.
Seeking Alpha • Oct 10

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Acorda Therapeutics (NASDAQ:ACOR) said it withdrew a proposal  requesting to increase the number of company's authorized shares. The company is scheduled to hold a special meeting of stockholders on Nov. 4, where several proposals would be put to vote. Meanwhile, a proposal for authorization of a reverse stock split remains on the ballot and the board has asked the shareholders to vote in favor of the request, the company said in an Oct. 10 press release. "However, the proposal to implement a reverse split of Acorda's stock remains critical to ensure that we can get the stock price above $1.00, which would prevent the company from being delisted by Nasdaq. If that were to occur, we could be in default on our obligations to our debtholders and may be required to declare bankruptcy or liquidate, which would be adverse to the interests of shareholders and patients," said Acorda's President and CEO Ron Cohen. ACOR +10.81% to $0.41 premarket Oct. 10
Seeking Alpha • Aug 29

Acorda inks license deal with Asieris for pre-clinical drug

Commercial-stage biopharmaceutical company Acorda Therapeutics (NASDAQ:ACOR) announced a license agreement with Chinese biotech Asieris Pharmaceuticals on Monday for the preclinical candidate, Nepicastat. Per the terms, the two companies will collaborate to develop Nepicastat, a small molecule drug for non-psychiatric indications and therapeutic uses. In return, Acorda (ACOR) is set to receive $500K of upfront payment, up to $7M of fees based on regulatory milestones, and a royalty on future net sales. Acorda (ACOR) U.S. subsidiary, Biotie Therapies, Inc., owns the rights for Nepicastat. Read: In June, the nano-cap ACRO stock surged in reaction to the launch of its inhalational Parkinson’s disease drug Inbrija in Germany. However, the company shares remain ~90% below the year-ago level, as indicated in this graph.
Seeking Alpha • Aug 19

Acorda Therapeutics announces resignation of COO

Acorda Therapeutics (NASDAQ:ACOR) has announced that Lauren Sabella, Chief Operating Officer, will resign from the Co. effective Sept. 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. Ms. Sabella’s responsibilities will be assumed by two of her current direct reports, Sofia Ali, Senior VP, Operations & Strategic Planning and Susan Way, Senior VP, Drug Development and Regulatory Affairs. ACOR +4.35% premarket to $0.48.
Seeking Alpha • Oct 04

Acorda Therapeutics: Managing The Transition

Today, we take our first look at Acorda Therapeutics which has two approved products on the market. One of these is seeing increasing generic competition while the other is ramping up sales.  The company recently announced a significant workforce reduction to reduce costs. Can Acorda manage this transition without diluting shareholders?  A full investment analysis follows in the paragraphs below.
Seeking Alpha • Jul 24

Acorda Therapeutics Continues To Maneuver For A Turnaround

Acorda Therapeutics continues to maneuver to set up for a potential turnaround in the coming years. The company recently announced a commercial partnership with Esteve Pharmaceuticals for INBRIJA in Spain. I expect additional European and Ex-U.S. partnerships are on the docket. Acorda was able to remove their debt that was due in 2021. Now, with that overhang removed, any progress made should be reflected in the share price. I update my plan for trading Acorda over the remainder of 2021 as we wait for the remaining quarterly earnings.
Analysis Article • May 26

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

The underwhelming share price performance of Acorda Therapeutics, Inc. ( NASDAQ:ACOR ) in the past three years would...
Analysis Article • Mar 09

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Acorda Therapeutics, Inc. ( NASDAQ:ACOR ) shareholders will have a reason to smile today, with the covering analyst...

Shareholder Returns

ACOR.QUS BiotechsUS Market
7D-28.5%-1.9%-4.1%
1Y-99.9%23.6%20.6%

Return vs Industry: ACOR.Q underperformed the US Biotechs industry which returned 9.2% over the past year.

Return vs Market: ACOR.Q underperformed the US Market which returned 16.9% over the past year.

Price Volatility

Is ACOR.Q's price volatile compared to industry and market?
ACOR.Q volatility
ACOR.Q Average Weekly Movement55.6%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: ACOR.Q's share price has been volatile over the past 3 months.

Volatility Over Time: ACOR.Q's weekly volatility has increased from 34% to 56% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995102Ron Cohenwww.acorda.com

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

Acorda Therapeutics, Inc. Fundamentals Summary

How do Acorda Therapeutics's earnings and revenue compare to its market cap?
ACOR.Q fundamental statistics
Market capUS$37.39k
Earnings (TTM)-US$263.42m
Revenue (TTM)US$115.66m
0.0x
P/S Ratio
0.0x
P/E Ratio

Is ACOR.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACOR.Q income statement (TTM)
RevenueUS$115.66m
Cost of RevenueUS$20.48m
Gross ProfitUS$95.19m
Other ExpensesUS$358.61m
Earnings-US$263.42m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-212.08
Gross Margin82.30%
Net Profit Margin-227.75%
Debt/Equity Ratio-103.1%

How did ACOR.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/13 04:38
End of Day Share Price 2024/08/13 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Acorda Therapeutics, Inc. is covered by 20 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerAegis Capital Corporation
Christopher RaymondBaird
Kenneth TrbovichBrean Capital Historical (Janney Montgomery)